Share on StockTwits

Several investment firms have updated their stock ratings and price targets on shares of AcelRx Pharmaceuticals (NASDAQ: ACRX) in the last week:

  • AcelRx Pharmaceuticals was downgraded by analysts at Canaccord Genuity from a “buy” rating to a “hold” rating. They now have a $8.00 price target on the stock, down previously from $16.00.
  • AcelRx Pharmaceuticals had its price target lowered by analysts at RBC Capital from $15.00 to $12.00. They now have an “outperform” rating on the stock.
  • AcelRx Pharmaceuticals had its price target lowered by analysts at JMP Securities from $14.00 to $12.00. They now have an “outperform” rating on the stock.
  • AcelRx Pharmaceuticals had its price target lowered by analysts at Mizuho from $20.00 to $15.00. They now have a “buy” rating on the stock.
  • AcelRx Pharmaceuticals had its price target lowered by analysts at Roth Capital to $16.00. They now have a “buy” rating on the stock.
  • AcelRx Pharmaceuticals was downgraded by analysts at Piper Jaffray from an “overweight” rating to a “neutral” rating. They now have a $8.00 price target on the stock, down previously from $14.00.
  • AcelRx Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Cowen and Company. They now have a $14.00 price target on the stock, down previously from $15.00.

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) opened at 6.41 on Thursday. AcelRx Pharmaceuticals Inc has a one year low of $6.04 and a one year high of $13.64. The stock’s 50-day moving average is $9.54 and its 200-day moving average is $10.49. The company’s market cap is $277.7 million.

AcelRx Pharmaceuticals, Inc is a United States-based Pharmaceutical Company, which develops and commercializes therapies for the treatment of pain.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.